{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T15:53:17Z","timestamp":1791215597803,"version":"4.1.0"},"reference-count":24,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2012,3,27]],"date-time":"2012-03-27T00:00:00Z","timestamp":1332806400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Transfusion"],"published-print":{"date-parts":[[2012,7]]},"abstract":"<jats:p><jats:bold>BACKGROUND:<\/jats:bold> Babesiosis is the most common transfusion\u2010transmitted infection reported to the Food and Drug Administration (FDA). We developed and implemented the first laboratory\u2010based blood donor screening program for <jats:italic>Babesia microti<\/jats:italic> to help reduce and prevent transfusion\u2010transmitted babesiosis (TTB) and report results for the initial year.<\/jats:p><jats:p><jats:bold>STUDY DESIGN AND METHODS:<\/jats:bold> Selective <jats:italic>B.\u2003microti<\/jats:italic> donor screening was performed using real\u2010time polymerase chain reaction (PCR) and indirect immunofluorescence assay (IFA) to reduce the incidence of TTB in neonates and pediatric sickle cell and thalassemia patients under an FDA\u2010approved investigational new drug application. We compared the reports of TTB in these patients in the first 12 months of the study with those of patients who received unscreened blood from 2005 to 2010.<\/jats:p><jats:p><jats:bold>RESULTS:<\/jats:bold> There were 2113 units tested with 2086 negative results, 26 positive IFA results (1.23%), and one indeterminate PCR result (0.05%). No reported case of TTB occurred with any <jats:italic>B.\u2003microti<\/jats:italic>\u2013screened unit transfused to the targeted patients (0\/787 units) or to any patient who received the screened units (0\/2086 units). Before screening, there were seven cases of TTB in neonates, sickle cell, and thalassemia patients from 6500 unscreened units (one case\/929 units) and 24 cases in the total transfused population from 496,545 units distributed (one case\/20,686 units).<\/jats:p><jats:p><jats:bold>CONCLUSION:<\/jats:bold> Implementation of <jats:italic>B.\u2003microti<\/jats:italic> IFA and PCR screening is compatible with blood center operations to provide tested units. While the results after 1 year are not powered to demonstrate a change in the rate of TTB after testing, they are encouraging.<\/jats:p>","DOI":"10.1111\/j.1537-2995.2012.03612.x","type":"journal-article","created":{"date-parts":[[2012,3,27]],"date-time":"2012-03-27T20:21:50Z","timestamp":1332879710000},"page":"1523-1529","source":"Crossref","is-referenced-by-count":71,"title":["Preventing transfusion\u2010transmitted babesiosis: preliminary experience of the first laboratory\u2010based blood donor screening program"],"prefix":"10.1111","volume":"52","author":[{"given":"Carolyn","family":"Young","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjulika","family":"Chawla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Berardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Padbury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gail","family":"Skowron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"Krause","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the Babesia Testing Investigational Containment Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,3,27]]},"reference":[{"key":"e_1_2_8_2_2","doi-asserted-by":"crossref","unstructured":"VannierE KrausePJ.Update on babesiosis. Interdisciplinary Perspectives on Infectious Diseases.2009.","DOI":"10.1155\/2009\/984568"},{"key":"e_1_2_8_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198011063031906"},{"key":"e_1_2_8_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00022-10"},{"key":"e_1_2_8_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2009.02494.x"},{"key":"e_1_2_8_6_2","doi-asserted-by":"publisher","DOI":"10.1086\/595010"},{"key":"e_1_2_8_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2009.02317.x"},{"key":"e_1_2_8_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/170.1.231"},{"key":"e_1_2_8_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2010.02851.x"},{"key":"e_1_2_8_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2009.02380.x"},{"key":"e_1_2_8_11_2","unstructured":"Food and Drug Administration.Biological product and hematopoietic cell therapy\/product (HCT\/P) deviation report\u2014annual summary for fiscal year 2008 Table 15. [cited 2012 Mar 3]. Available from: URL:http:\/\/www.fda.gov\/downloads\/BiologicsBloodVaccines\/SafetyAvailability\/ReportaProblem\/BiologicalProductDeviations\/UCM170057.pdf"},{"key":"e_1_2_8_12_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-155-8-201110180-00362"},{"key":"e_1_2_8_13_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2010-0502"},{"key":"e_1_2_8_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2011.03.009"},{"key":"e_1_2_8_15_2","unstructured":"Rhode Island Department of Health Division of Infectious Disease and Epidemiology.Infectious disease data.2011. [cited 2011 Oct 29]. Available from: URL:http:\/\/www.health.ri.gov\/data\/communicablediseases\/index.php"},{"key":"e_1_2_8_16_2","doi-asserted-by":"crossref","unstructured":"MenisM AndersonSA IzurietaHS KumarS BurwenDR GibbsJ KroppG ErtenT MaCurdyTE WorrallCM KelmanJA WalderhaugMO.Babesiosis among elderly Medicare beneficiaries United States 2006\u20102008.2012. [cited 2011 Nov 29]. Available from: URL:http:\/\/www.health.ri.gov\/data\/communicablediseases\/Babesiosis.pdf","DOI":"10.3201\/eid1801.110305"},{"key":"e_1_2_8_17_2","doi-asserted-by":"publisher","DOI":"10.1086\/525852"},{"key":"e_1_2_8_18_2","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.1978.27.14"},{"key":"e_1_2_8_19_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/169.4.923"},{"key":"e_1_2_8_20_2","unstructured":"DevineP BerardiV MolloyP BrissetteE HewinsME YoungC.Babesia microti Tests for blood donor screening.2011. Abstract at 2011 AABB National Meeting San Diego."},{"key":"e_1_2_8_21_2","article-title":"Lookback investigations of Babesia microti\u2010seropositive blood donors:seven\u2010year experience in a Babesia\u2010endemic area","author":"Johnson ST","year":"2011","journal-title":"Transfusion"},{"key":"e_1_2_8_22_2","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.1981.30.291"},{"key":"e_1_2_8_23_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197710132971511"},{"key":"e_1_2_8_24_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199807163390304"},{"key":"e_1_2_8_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2009.02429.x"}],"container-title":["Transfusion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1537-2995.2012.03612.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1537-2995.2012.03612.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T17:38:06Z","timestamp":1697305086000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1537-2995.2012.03612.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3,27]]},"references-count":24,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2012,7]]}},"alternative-id":["10.1111\/j.1537-2995.2012.03612.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1537-2995.2012.03612.x","archive":["Portico"],"relation":{},"ISSN":["0041-1132","1537-2995"],"issn-type":[{"value":"0041-1132","type":"print"},{"value":"1537-2995","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,3,27]]}}}